Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.

Tencent Trusted Doctors has partnered China Resources' CR Capital fund to establish a healthcare industry fund focusing on the city of Chengdu.

The autoreactive and neuro-inflammatory disease therapy developer closed a $77.5m round co-led by Sanofi Ventures that took its total funding to more than $117m.

The precision medicine developer attracted returning investors Novo, Novartis Venture Fund and Johnson & Johnson Innovation – JJDC for a crossover financing round.

Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

The investment firm supplied $50m for telehealth platform developer MDLive, which already counts Sentara, Cigna, Sutter Health, Novo and HCSC as investors.

The Johns Hopkins spinout has raised cash from OUP as it looks to move its first candidate, targeting skin itch complications, into the clinic.

China Life has returned for a $142m series D-plus round for cancer treatment developer Biocytogen, having already co-led its $77m series D round 13 months ago.

Mission Bay Capital has placed a bet on Symbiome, creators of a skin care range intended to emulate our ancestor’s microbiome.

Cordovan Capital Partners has sold its stake in QUB-founded clinician training equipment supplier TruCorp at a 10.4-fold return.